avapro has been researched along with Proteinuria in 42 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to assess the efficacy and safety of Rehmannia glutinosa acteosides used in combination with the angiotensin receptor blocker irbesartan to treat primary chronic glomerulonephritis." | 9.19 | Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial. ( Cao, L; Chen, F; Fan, W; Feng, P; Fu, P; Gou, Z; Liang, Y; Liu, F; Qiu, H; Shi, M; Shi, P; Zhong, H; Zhou, L; Zuo, C, 2014) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 9.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 8.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| " ARB treatment ameliorates proteinuria in PAN nephropathy by inhibiting the reduction of NEPH1 and nephrin." | 7.80 | Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. ( Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M, 2014) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 5.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "This study aims to assess the efficacy and safety of Rehmannia glutinosa acteosides used in combination with the angiotensin receptor blocker irbesartan to treat primary chronic glomerulonephritis." | 5.19 | Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial. ( Cao, L; Chen, F; Fan, W; Feng, P; Fu, P; Gou, Z; Liang, Y; Liu, F; Qiu, H; Shi, M; Shi, P; Zhong, H; Zhou, L; Zuo, C, 2014) |
| "The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood." | 5.12 | Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006) |
| "Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial." | 5.11 | Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005) |
| "In nonnephrotic NPGN patients, standard doses of either ramipril or irbesartan lead to significant reduction of residual proteinuria and amelioration of the qualitative features suggestive of tubular damage." | 5.10 | Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. ( Balletta, MM; Bellizzi, V; Conte, G; D'Amora, M; De Nicola, L; Giannattasio, P; Iodice, C; Minutolo, R; Rinaldi, G; Signoriello, G; Tuccillo, S, 2003) |
| "In children with chronic kidney disease the effects of the angiotensin II antagonist irbesartan on arterial pressure and proteinuria mimic those observed with the converting enzyme inhibitors." | 5.09 | Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. ( Bianchetti, MG; Teuffel, O; von Vigier, RO; Zberg, PM, 2000) |
| "Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago." | 4.83 | Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006) |
| " Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia." | 4.82 | Outcome studies in diabetic nephropathy. ( Mohanram, A; Toto, RD, 2003) |
| "Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria." | 4.82 | Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| " The PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; Safety and efficacy in paTieNts with hypERtension) study is a prospective specific clinical use survey examining the efficacy and safety of 12-week treatment with amlodipine (AML) and Angiotensin II Receptor Blocker (ARB) in 5900 hypertensive patients." | 3.81 | The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor ( Fukuda, H; Ishibashi, K; Ishimitsu, T; Nagao, M; Nukui, K; Sato, F; Uchida, M, 2015) |
| " ARB treatment ameliorates proteinuria in PAN nephropathy by inhibiting the reduction of NEPH1 and nephrin." | 3.80 | Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. ( Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M, 2014) |
| "Short treatment duration, lower pretreatment proteinuria than expected." | 2.90 | Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. ( Aparicio, C; Bellasi, A; Cannata, A; Cozzolino, M; Ferrari, S; Kohan, DE; Lecchi, V; Mallamaci, F; Mazzaferro, S; Peraro, F; Perna, A; Perticucci, E; Remuzzi, G; Rotondi, S; Ruggenenti, P; Ruggiero, B; Tartaglione, L; Trillini, M; Tripepi, R; Villa, D; Zoccali, C, 2019) |
| " Sparsentan was safe and well tolerated." | 2.87 | DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. ( Adler, S; Campbell, KN; Chaudhuri, A; Derebail, VK; Gambaro, G; Gesualdo, L; Gipson, DS; Hogan, J; Komers, R; Lieberman, K; Marder, B; Meyers, KE; Mustafa, E; Nelson, P; Radhakrishnan, J; Srivastava, T; Stepanians, M; Tesar, V; Trachtman, H; Zhdanova, O, 2018) |
| "Total effective rate in treating proteinuria in high-dose group was 72." | 2.76 | [The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease]. ( Chen, XD; Li, X; Li, ZX, 2011) |
| "Patients with high blood pressure are often overweight or even obese." | 2.71 | [Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. ( Bramlage, P; Kirch, W; Sharma, AM, 2004) |
| "When indomethacin was added to enalapril treatment, a further significant reduction in urinary proteins and fractional albumin clearance was observed." | 2.69 | The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. ( Azzollini, N; Mister, M; Perico, N; Remuzzi, A; Remuzzi, G; Ruggenenti, P; Sangalli, F, 1998) |
| "Patients with type 2 diabetes and diabetic nephropathy have a dramatically increased cardiovascular risk." | 2.42 | Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003) |
| "Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy." | 2.41 | The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002) |
| "The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression." | 1.38 | Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012) |
| "Proteinuria was markedly attenuated in the sulodexide-treated groups." | 1.38 | Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. ( Chen, XM; Li, P; Ma, LL; Wang, JZ; Wei, RB; Xie, RJ; Xie, YS; Yin, M, 2012) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 1.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "In pediatric patients with chronic kidney diseases, irbesartan given once a day for 18 weeks significantly reduces arterial pressure and proteinuria, with an excellent tolerability and side effect profile." | 1.31 | Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. ( Bianchetti, MG; Casaulta-Aebischer, C; Fossali, E; Franscini, LM; Pfister, R; Von Vigier, RO, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (7.14) | 18.2507 |
| 2000's | 25 (59.52) | 29.6817 |
| 2010's | 14 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hsu, FY | 1 |
| Lin, FJ | 1 |
| Ou, HT | 1 |
| Huang, SH | 1 |
| Wang, CC | 1 |
| Trachtman, H | 1 |
| Nelson, P | 1 |
| Adler, S | 1 |
| Campbell, KN | 1 |
| Chaudhuri, A | 1 |
| Derebail, VK | 1 |
| Gambaro, G | 2 |
| Gesualdo, L | 1 |
| Gipson, DS | 1 |
| Hogan, J | 1 |
| Lieberman, K | 1 |
| Marder, B | 1 |
| Meyers, KE | 1 |
| Mustafa, E | 1 |
| Radhakrishnan, J | 1 |
| Srivastava, T | 1 |
| Stepanians, M | 1 |
| Tesar, V | 1 |
| Zhdanova, O | 1 |
| Komers, R | 1 |
| Ruggiero, B | 1 |
| Trillini, M | 1 |
| Tartaglione, L | 1 |
| Rotondi, S | 1 |
| Perticucci, E | 1 |
| Tripepi, R | 1 |
| Aparicio, C | 1 |
| Lecchi, V | 1 |
| Perna, A | 1 |
| Peraro, F | 1 |
| Villa, D | 1 |
| Ferrari, S | 1 |
| Cannata, A | 1 |
| Mazzaferro, S | 1 |
| Mallamaci, F | 1 |
| Zoccali, C | 1 |
| Bellasi, A | 1 |
| Cozzolino, M | 1 |
| Remuzzi, G | 3 |
| Ruggenenti, P | 2 |
| Kohan, DE | 1 |
| Qiu, H | 1 |
| Fu, P | 1 |
| Fan, W | 1 |
| Zuo, C | 1 |
| Feng, P | 1 |
| Shi, P | 1 |
| Cao, L | 1 |
| Liu, F | 1 |
| Zhou, L | 1 |
| Chen, F | 1 |
| Zhong, H | 1 |
| Gou, Z | 1 |
| Liang, Y | 1 |
| Shi, M | 1 |
| Wang, H | 2 |
| Mu, W | 1 |
| Zhai, J | 1 |
| Xing, D | 1 |
| Miao, S | 1 |
| Wang, J | 1 |
| Deng, Y | 1 |
| Wang, N | 1 |
| Chen, H | 1 |
| Yang, H | 1 |
| He, X | 1 |
| Shang, H | 1 |
| Linz, D | 1 |
| Mahfoud, F | 1 |
| Linz, B | 1 |
| Hohl, M | 1 |
| Schirmer, SH | 1 |
| Wirth, KJ | 1 |
| Böhm, M | 1 |
| Takahashi, A | 1 |
| Fukusumi, Y | 1 |
| Yamazaki, M | 1 |
| Kayaba, M | 1 |
| Kitazawa, Y | 1 |
| Tomita, M | 1 |
| Kawachi, H | 1 |
| Ishimitsu, T | 1 |
| Fukuda, H | 1 |
| Uchida, M | 1 |
| Ishibashi, K | 1 |
| Sato, F | 1 |
| Nukui, K | 1 |
| Nagao, M | 1 |
| Ferraro, PM | 1 |
| Ferraccioli, GF | 1 |
| Fulignati, P | 1 |
| Costanzi, S | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| Evans, M | 1 |
| Bain, SC | 1 |
| Hogan, S | 1 |
| Bilous, RW | 1 |
| Li, X | 1 |
| Chen, XD | 1 |
| Li, ZX | 1 |
| Ros-Ruiz, S | 1 |
| Aranda-Lara, P | 1 |
| Fernández, JC | 1 |
| Martínez-Esteban, MD | 1 |
| Jironda, C | 1 |
| Hidalgo, P | 1 |
| Hernández-Marrero, D | 1 |
| Li, P | 1 |
| Ma, LL | 1 |
| Xie, RJ | 1 |
| Xie, YS | 1 |
| Wei, RB | 1 |
| Yin, M | 1 |
| Wang, JZ | 1 |
| Chen, XM | 1 |
| Tsuruoka, S | 1 |
| Kai, H | 1 |
| Usui, J | 1 |
| Morito, N | 1 |
| Saito, C | 1 |
| Yoh, K | 1 |
| Yamagata, K | 1 |
| Zanella, MT | 1 |
| Ribeiro, AB | 2 |
| Franscini, LM | 1 |
| Von Vigier, RO | 3 |
| Pfister, R | 1 |
| Casaulta-Aebischer, C | 1 |
| Fossali, E | 2 |
| Bianchetti, MG | 3 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Iodice, C | 1 |
| Balletta, MM | 1 |
| Minutolo, R | 1 |
| Giannattasio, P | 1 |
| Tuccillo, S | 1 |
| Bellizzi, V | 1 |
| D'Amora, M | 1 |
| Rinaldi, G | 1 |
| Signoriello, G | 1 |
| Conte, G | 1 |
| De Nicola, L | 1 |
| Mohanram, A | 1 |
| Toto, RD | 1 |
| Lewis, EJ | 4 |
| Lewis, JB | 3 |
| Li, S | 1 |
| Cao, B | 1 |
| Feng, QH | 1 |
| Li, XZ | 1 |
| Ruilope, LM | 1 |
| Segura, J | 1 |
| Hunsicker, LG | 3 |
| Atkins, RC | 2 |
| Braden, G | 2 |
| de Crespigny, PJ | 1 |
| DeFerrari, G | 2 |
| Drury, P | 2 |
| Locatelli, F | 2 |
| Wiegmann, TB | 2 |
| Lehnert, H | 1 |
| Bramlage, P | 3 |
| Pittrow, D | 1 |
| Kirch, W | 2 |
| Briganti, EM | 1 |
| Champion de Crespigny, PJ | 1 |
| Vogt, L | 1 |
| Navis, G | 1 |
| de Zeeuw, D | 1 |
| de Gracia, MC | 1 |
| Molina, M | 1 |
| Navarro, MJ | 1 |
| Garcia Hernández, MA | 1 |
| Sharma, AM | 1 |
| Gavras, H | 1 |
| Simonetti, GD | 1 |
| Konrad, M | 1 |
| Rizzi, M | 1 |
| Thoenes, M | 1 |
| Paar, WD | 1 |
| Bramlage, CP | 1 |
| Schmieder, RE | 1 |
| Lapinski, R | 1 |
| Perico, N | 2 |
| Remuzzi, A | 2 |
| Sangalli, F | 2 |
| Benigni, A | 1 |
| Ziai, F | 1 |
| Ots, M | 1 |
| Provoost, AP | 1 |
| Troy, JL | 1 |
| Rennke, HG | 1 |
| Brenner, BM | 1 |
| Mackenzie, HS | 1 |
| Azzollini, N | 1 |
| Mister, M | 1 |
| Zhou, A | 1 |
| Yu, L | 1 |
| Li, J | 1 |
| Zhang, J | 1 |
| Zberg, PM | 1 |
| Teuffel, O | 1 |
| Bold, KO | 1 |
| De Rosa, ML | 1 |
| de Cristofaro, A | 1 |
| Rossi, M | 1 |
| Baiano, A | 1 |
| Cardace, P | 1 |
| Albanese, L | 1 |
| Vigorito, C | 1 |
| Rodby, RA | 1 |
| Ferrari, P | 1 |
| Marti, HP | 1 |
| Pfister, M | 1 |
| Frey, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Multicenter, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess the Renal and Humoral Effects of Sevelamer Carbonate in Patients With Chronic Kidney Disease and Residual Proteinuria Despite Best Available Treatment[NCT01968759] | Phase 2 | 53 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612] | 150 participants (Anticipated) | Interventional | 2021-12-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for avapro and Proteinuria
| Article | Year |
|---|---|
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2002 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Outcome studies in diabetic nephropathy.
Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme | 2003 |
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin | 2003 |
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial | 2003 |
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetic Nephropathies; Humans; Irbesar | 2004 |
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds | 2006 |
19 trials available for avapro and Proteinuria
| Article | Year |
|---|---|
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Child; Creatinine; Dose-Response R | 2018 |
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Chelating Agents; Cross-Over Studies; Drug Monitoring; Dru | 2019 |
Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Female; Glomerul | 2014 |
The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
Topics: Administration, Oral; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Com | 2013 |
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl C | 2009 |
[The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease].
Topics: Adult; Aged; Biphenyl Compounds; Female; Humans; Irbesartan; Male; Middle Aged; Prospective Studies; | 2011 |
High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetic Nephropathies; Fe | 2012 |
Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Biphe | 2013 |
Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Creati | 2003 |
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2003 |
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nep | 2005 |
Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?
Topics: Adolescent; Adult; Aged; Biological Availability; Biphenyl Compounds; Confidence Intervals; Dose-Res | 2005 |
[Effect of irbesartan in proteinuric non-diabetic renal disease].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Female; Humans; Irbesartan; Kidn | 2005 |
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C | 2004 |
Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child; Chil | 2006 |
The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflam | 1998 |
Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
Topics: Adolescent; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2000 |
Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Drug Administr | 2001 |
A clinical trial in type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block | 2001 |
16 other studies available for avapro and Proteinuria
| Article | Year |
|---|---|
Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds | 2017 |
Effect of obstructive respiratory events on blood pressure and renal perfusion in a pig model for sleep apnea.
Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Disea | 2014 |
Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Diseas | 2014 |
The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure | 2015 |
Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Ca | 2010 |
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di | 2012 |
Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Bl | 2012 |
Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.
Topics: Adolescent; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pre | 2002 |
[Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibiotics, Antineoplastic; Biphenyl Com | 2003 |
[Albuminuria: an indicator of cardiovascular risk].
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensi | 2007 |
Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Capillaries; Capillar | 1996 |
The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1996 |
Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou | 2000 |
[Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To | 2001 |
Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound | 2002 |
Preventing nephropathy in patients with type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty | 2002 |